Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Abstract: Complicated deformation problems are frequently encountered in medical image registration tasks. Although various advanced registration models have been proposed, accurate and efficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback